Ganging up on HCV
There has long been agreement in the clinical community that in certain diseases it would make sense to test two unapproved compounds together rather than adding each separately to an approved regimen and waiting to combine them until at least one reaches the market. But the regulatory pitfalls of proving which compound contributes what degree of efficacy and side effects have discouraged such efforts.
A case in point is HCV, in which combining several compounds with the potential to block multiple aspects of viral replication ultimately could supplant the suboptimal interferon-based standard of care.
Despite a lack of regulatory clarity from FDA